Compare ATOM & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | CRBU |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 203.9M |
| IPO Year | 2016 | 2021 |
| Metric | ATOM | CRBU |
|---|---|---|
| Price | $4.06 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.41 | 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,000.00 | N/A |
| Revenue This Year | $527.69 | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $0.66 |
| 52 Week High | $7.45 | $3.53 |
| Indicator | ATOM | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 51.56 |
| Support Level | $3.14 | $1.70 |
| Resistance Level | $5.41 | $2.07 |
| Average True Range (ATR) | 0.44 | 0.12 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 1.02 | 52.44 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.